GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » Debt-to-EBITDA
中文

Invitae (Invitae) Debt-to-EBITDA : -0.41 (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Invitae Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Invitae's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $48.5 Mil. Invitae's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1,459.9 Mil. Invitae's annualized EBITDA for the quarter that ended in Sep. 2023 was $-3,642.7 Mil. Invitae's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.41.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Invitae's Debt-to-EBITDA or its related term are showing as below:

NVTAQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.04   Med: -0.49   Max: -0.08
Current: -1.18

During the past 11 years, the highest Debt-to-EBITDA Ratio of Invitae was -0.08. The lowest was -6.04. And the median was -0.49.

NVTAQ's Debt-to-EBITDA is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.8 vs NVTAQ: -1.18

Invitae Debt-to-EBITDA Historical Data

The historical data trend for Invitae's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae Debt-to-EBITDA Chart

Invitae Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.70 -1.38 -0.70 -6.04 -0.59

Invitae Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.77 -8.22 -2.76 -2.36 -0.41

Competitive Comparison of Invitae's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Invitae's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invitae's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invitae's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Invitae's Debt-to-EBITDA falls into.



Invitae Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Invitae's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(19.721 + 1731.282) / -2952.379
=-0.59

Invitae's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(48.505 + 1459.874) / -3642.748
=-0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Invitae  (OTCPK:NVTAQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Invitae Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Invitae's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Invitae (Invitae) Business Description

Traded in Other Exchanges
Address
1400 16th Street, San Francisco, CA, USA, 94103
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
Executives
Ana J. Schrank officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley officer: Chief Commercial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey officer: See Remarks 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons officer: See remarks 2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum officer: Chief Medical Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida officer: General Counsel 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight officer: Chief Operating Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne director 1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George director, officer: CEO 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer officer: Chief Financial Officer 1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland officer: Chief Commercial Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse director 3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers director, other: President, Oncology C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301

Invitae (Invitae) Headlines

From GuruFocus

Q3 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Invitae Corp to Acquire Ciitizen Corp M&A Call Transcript

By GuruFocus Research 02-14-2024

Q4 2021 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2021 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2020 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024